Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 2)

ABSTRACT: Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 2)

PROVIDER: PRJNA647379 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12269873.fastq.gz	Fastqsanger.gz
	SRR12269874.fastq.gz	Fastqsanger.gz
	SRR12269875.fastq.gz	Fastqsanger.gz
	SRR12269876.fastq.gz	Fastqsanger.gz
	SRR12269877.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 1)

Project description:Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 1)

| PRJNA647380 | ENA

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 3)

Project description:Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 3)

| PRJNA647381 | ENA

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity

Project description:Characterization of novel natural compound derivatives with cancer-selective cytotoxicity

| PRJNA647378 | ENA

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 3)

Project description:Colorectal cancer is one of the most frequent and lethal cancer in the world. Current therapeutic approaches are still not fully successful, yet cause numerous and severe side effects for the patient. We screened chemically synthesized derivatives from two natural compounds (a-Mangostin and Paeonol) as potential novel chemicals that increase cancer cell selectivity over non-transformed human cells. We found two of them that efficiently induced cell cycle arrest and apoptosis in human cancer cells and organoids derived from tumor tissue without affecting the viability of human non-cancer cells and intestinal organoids derived from healthy tissue. Our findings increase the knowledge about cancer-specific compounds and propose two natural compound derivatives as potential novel chemotherapeutics.

2022-03-04 | GSE154754 | GEO

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 2)

2022-03-04 | GSE154753 | GEO

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity (RNA-seq dataset 1)

2022-03-04 | GSE154752 | GEO

Characterization of novel a-Mangostin and Paeonol derivatives with cancer-selective cytotoxicity

Project description:a-Mangostin and Paeonol have shown anti-cancer and anti-inflammatory properties, however these two natural compounds have no clinical value because of their low solubility and low membrane permeability. In this study, we screened chemically synthesized derivatives from these two natural compounds as potential novel chemicals that increase cancer cell cytotoxicity over non-transformed human cells. We found the two derivative compounds, named a-Mangostin-1 (aMan1) and Paeonol-1 (Pae1) more efficiently and specifically induced cytotoxicity in HCT116, HT-29, and SW48 colorectal cancer cell lines than the parental compounds. Both, aMan1 and Pae1 arrested HCT116 cells in G1 and HT-29 and SW48 cells in G2/M phase of the cell cycle. Both aMan1 and Pae1 induced apoptosis in human cancer cells, through a Caspase-dependent mechanism. aMan1 and Pae1 induced selective transcriptional responses in CRC cells involving genes related to metabolic stress and DNA damage response signaling pathways. Finally, experiments on primary colon organoids showed that both the novel derivatives kill organoids derived from cancer without affecting the viability of organoids derived from healthy tissue, where the parental compounds and the currently-used chemotherapeutic drug Irinotecan failed in. In conclusion, our findings increase the knowledge about natural compound derivatives as anticancer compounds and open new research options on the derivation of lead compounds aimed to the development of novel CRC chemotherapeutic drugs that selectively target cancer, but not healthy cells.

2023-03-11 | PXD024999 | Pride

Characterization of novel natural compound derivatives with cancer-selective cytotoxicity

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-04 | GSE154755 | GEO

NKCLR3 impairs natural killer cell cytotoxicity by epigenetically targeting the Natural Cytotoxicity Triggering Receptor 1 (NCR1)

Project description:RNA-Seq reveals that NKCLR3 (NK cytotoxicity-associated long noncoding RNA 3, NONHSAT026854) is differentially expressed in VPA-treated human NK cells. To determine whether it is functionally important in NK cell cytotoxicity, we used a RNA reverse transcription-associated trap sequencing (RAT-Seq) approach to profile the genome-wide binding targets for NKCLR3. This dataset will help study the mechanisms underlying the role of NKCLR3 in NK cell cytotoxicity.

2025-01-01 | GSE284721 | GEO

Assessment of Rocaglates and Targeted Derivatives as Selective Inhibitors of Glioblastoma Stem Cells

Project description:A substantial body of evidence suggests that the initiation, progression, and recurrence of glioblastomas (GBM) are driven by a small subpopulation (1-5%) of cells within the tumor known as tumor-initiating cells or cancer stem cells (CSCs). GBM CSCs play a pivotal role in orchestrating drug resistance mechanisms and tumor relapse. As a prospective avenue for GBM intervention, targeted suppression of GBM CSCs holds promise. In this study, we identified novel rocaglate derivatives (rocaglate acyl sulfamides (Roc ASFs)) that can inhibit GBM CSCs with nanomolar (nM) EC50s. Our findings, supported by comparative dose-response assays and functional characterizations, demonstrate that these derivatives exert a robust, dose-dependent cytotoxic impact on GBM CSCs. Furthermore, our investigations into target identification have unveiled the DEAD box helicase DDX3X as a specific target of Roc ASFs. Inhibiting DDX3X using Roc ASF derivatives confers selective cytotoxicity to GBM CSCs. These findings suggest a promising therapeutic strategy for targeting GBM CSCs.

2024-09-13 | GSE246936 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data